Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi




http://scihub22266oqcxt.onion/
suck pdf from google scholar
C4741846!4741846!26416413
unlimited free pdf from europmc26416413    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid26416413      Oncotarget 2015 ; 6 (37): 39564-77
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Multistep, effective drug distribution within solid tumors #MMPMID26416413
  • Shemi A; Khvalevsky EZ; Gabai RM; Domb A; Barenholz Y
  • Oncotarget 2015[Nov]; 6 (37): 39564-77 PMID26416413show ga
  • The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ?priming? enables drug penetration to successive cell layers. Tumor ?void volume? (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ?mixing?, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER? system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER? was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box